FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia.

Atham Ali Alvin Phan Vijaya P Vaikari Mincheol Park Mateusz Pospiech Ryan Chu Yiting Meng John Andrew MacKay Houda Alachkar

Published in: Cancer research communications (2024)

This study investigates a dual-targeting strategy in acute myeloid leukemia (AML), focusing on FLT3 and CD99. The approach demonstrates enhanced therapeutic potential, presenting a novel option for AML treatment.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
nk cells
cancer therapy
case report
drug delivery
acute lymphoblastic leukemia
tyrosine kinase